The psilocybin legislation has passed both houses of Washington State’s legislature. However, lawmakers will need to reconcile differences between the House and Senate versions before the measure is sent to the Governor. Jay Inslee (D).
The bill was approved by the House on Tuesday. Representatives voted 87-10 to send it back to the Senate. The body approved a committee amendment that would create a pilot program for clinical research to examine the effects of therapeutic psilocybin on trauma, mood, and substance abuse disorders in veterans and first responders.
Last month, the Senate passed a prior version of the bill that did not include the pilot program. The Senate can either agree with the amended legislation or ask the House for a retraction.
Rep. Nicole Macri (D), who added the pilot program to this bill through an amendment in the House, stated that Washington would be able to “respond to traumas that too many of our constituents are experiencing.”
“This bill will enable us to learn more how we can use psilocybin to address not only the trauma effects that our military veterans have experienced but also other behavioral health conditions,” Macri said. “And help us all work out how we move toward a regulated approach towards psilocybin within our state.”
The SB5263 bill was introduced in the session to provide a more comprehensive legalization proposal. As introduced by Senators. Jesse Salomon (D) and Liz Lovelett (D), it would have allowed adults 21 and older to lawfully use psilocybin under the care of trained, state-licensed facilitators–similar to the system approved by Oregon voters in 2020.
However, in Senate committees, centrist Democrats later gutted the bill and instead created a task force, advisory group, and task force to examine the issue and make recommendations about how the state should proceed.
Later , Macri was added to the clinical pilot program by an amendment late in House Appropriations Committee. This change would create a program that is led by the University of Washington (UW), to treat veterans diagnosed with PSTD, mood disorders, or substance abuse disorders.
Macri wrote Marijuana Moment last Wednesday that she first came up with the idea for a pilot program. However, she later modified the plan to make it more politically feasible.
Macri said, “I built upon that pilot idea by talking to the UW’s governor’s staff about a approach they thought would be valuable and that the governor might sign into law.” “My intention is to accelerate the regulatory process for psilocybin use as a wellness service, by sharing findings about its effectiveness under real-life circumstances.”
The lawmaker, whose District is in Seattle, stated that she received more constituent emails supporting the original Senate bill this session than any other.
She stated that Washington would be able to add something to this area of interest by adding the pilot to the bill. “Psilocybin clinical trials have been limited and focused on one disorder, with no comorbidities. They were conducted in controlled environments. This does not necessarily indicate the effectiveness of psilocybin under real-life circumstances.
The newly passed bill would require the UW’s clinical pilot program to offer psilocybin treatment services through approved pathways by the federal Food and Drug Administration.
Some critics, including the leaders of the Psychedelic Medical Alliance Washington (PMAW), fear that the half-step could slow down wider access to the program by encouraging legislators to delay further reforms until the study’s conclusion, which could take many years.
Tatiana Luz Quintana was one of the co-directors of the group. She said that PMAW had asked for a new type of pilot program. It would send Washingtonians to Oregon instead to receive legal psilocybin service there.
She said that she hoped the FDA trial would provide real-world information to legislators about the results for clients who have received psilocybin. “This will also allow us to reintroduce the [legalization] bill next fiscal year. A FDA trial won’t offer meaningfully wider access.
Macri said that she had discussed the issue with colleagues, and that “on balance, feel like adding pilot will actually help over the long-term.”
“Most legislators are open for implementing a regulatory framework but many still have questions and concerns.” Marijuana Moment’s Sheri said that she was actually pleasantly surprised by how fast this issue gained momentum. “But, it was also clear to me this time that most of my colleagues want more information before allowing wide access.”
Anthony Back, a Seattle physician and professor of medicine at UW, spoke to lawmakers earlier this year. He is currently leading a clinical study of psilocybin assisted therapy for nurses and doctors with depression related to their work on the COVID pandemic.
Back testified before a Senate committee, “Obviously it would have been wonderful if we could delay until the incredibly definitive results from everything.” “But I can tell you that I have witnessed remarkable responses from clinicians suffering from a condition that prevented them performing the work that they love.
He also warned legislators that depriving adults of legal psilocybin poses its own set safety and health risks.
He said that he had heard of “desperate clinicians” who sought underground care. “Including a nurse who was sexually assaulted and unlicensed by an underground provider.”
Other drug policy bills in Washington have been passed through both houses this session. However, they are still awaiting Senate action on the different versions of the House measures.
The House approved a measure Wednesday that would allow state-licensed businesses to engage in interstate cannabis commerce if federal officials approve it. The measure, according to supporters, will allow Washington cannabis companies to export to states that do not have a marijuana system. The Senate approved version of the measure was amended to correct a typo. Now, the measure is back in the original chamber for concurrence.
Another measure that is on the verge to becoming law would ban employers from discriminating against applicants for jobs who have used or tested positive in marijuana use before they are hired . Workers who are already employed would not be protected.
Washington Lawmakers Are Set To Pass Interstate Marijuana Sales Bill
Photo by Wikimedia/Workman
The post Washington State is poised to enact Psilocybin bill, but fate of pilot program not certain as end of session nears appeared originally on Marijuana Moment.
